TGF-β2 Reduces the Cell-Mediated Immunogenicity of Equine MHC-Mismatched Bone Marrow-Derived Mesenchymal Stem Cells Without Altering Immunomodulatory Properties

Allogeneic mesenchymal stem cells (MSCs) are a promising cell therapy for treating numerous diseases, but major histocompatibility complex (MHC)-mismatched MSCs can be rejected by the recipient’s immune system. Pre-treating MSCs with transforming growth factor-β2 (TGF-β2) to downregulate surface exp...

Descripción completa

Detalles Bibliográficos
Autores principales: Berglund, Alix K., Long, Julie M., Robertson, James B., Schnabel, Lauren V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cell and Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889809/
https://www.ncbi.nlm.nih.gov/pubmed/33614658
http://dx.doi.org/10.3389/fcell.2021.628382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889809/
https://www.ncbi.nlm.nih.gov/pubmed/33614658
http://dx.doi.org/10.3389/fcell.2021.628382

Ejemplares similares